In vivo structure - Activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors

ACS Chemical Biology

Volumn 5, Issue 2, 2010, Pages 245-253

  Hao, Jijun ^a   Ho, Joshua N ^a   Lewis, Jana A ^b   Karim, Kaleh A ^a   Daniels, R Nathan ^b   Gentry, Patrick R ^b,c   Hopkins, Corey R ^b,c   Lindsley, Craig W ^b,c   Hong, Charles C ^a,b,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Veterans Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYTOKINE RECEPTOR ANTAGONIST; DORSOMORPHIN 1; DORSOMORPHIN 2; DORSOMORPHIN 3; DORSOMORPHIN 4; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; EMBRYO; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ZEBRA FISH;

ANIMALS; BONE MORPHOGENETIC PROTEINS; DRUG EVALUATION, PRECLINICAL; EMBRYO, NONMAMMALIAN; PYRAZOLES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ZEBRAFISH;

DANIO RERIO; VERTEBRATA;

EID: 77449108244     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb9002865     Document Type: Article

References (35)

1. MacCoss, M., and Baillie, T. A. (2004) Organic chemistry in drug discovery, Science 303, 1810-1813.
2. Zon, L. I., and Peterson, R. T. (2005) In vivo drug discovery in the zebrafish, Nat. Rev. Drug Discovery 4, 35-44.
3. Molina, G., Vogt, A., Bakan, A., Dai, W., Queiroz De Oliveira, P., Znosko, W., Smithgall, T. E., Bahar, I., Lazo, J. S., Day, B. W., and Tsang, M. (2009) Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages, Nat. Chem. Biol. 5, 680-687.
4. MacRae, C. A., and Peterson, R. T. (2003) Zebrafish-based small molecule discovery, Chem. Biol. 10, 901-908.
5. Hong, C. C. (2009) Large-scale small-molecule screen using zebrafish embryos, Methods Mol. Biol. (Clifton, N.J.) 486, 43-55.
6. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Delivery Rev. 46, 3-26. (Pubitemid 33653411)
7. Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., Lin, H. Y., Bloch, K. D., and Peterson, R. T. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism, Nat. Chem. Biol. 4, 33-41.
8. Hao, J., Daleo, M. A., Murphy, C. K., Yu, P. B., Ho, J. N., Hu, J., Peterson, R. T., Hatzopoulos, A. K., and Hong, C. C. (2008) Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells, PLoS ONE 3, e2904.
9. Yu, P. B., Deng, D. Y., Lai, C. S., Hong, C. C., Cuny, G. D., Bouxsein, M. L., Hong, D. W., McManus, P. M., Katagiri, T., Sachidanandan, C., Kamiya, N., Fukuda, T., Mishina, Y., Peterson, R. T., and Bloch, K. D. (2008) BMP type I receptor inhibition reduces heterotopic [corrected] ossification, Nat. Med. 14, 1363-1369.
10. Shen, Q., Little, S. C., Xu, M., Haupt, J., Ast, C., Katagiri, T., Mundlos, S., Seemann, P., Kaplan, F. S., Mullins, M. C., and Shore, E. M. (2009) The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization, J. Clin. Invest. 119, 3462-3472.
11. Kaplan, F. S., Xu, M., Seemann, P., Connor, J. M., Glaser, D. L., Carroll, L., Delai, P., Fastnacht-Urban, E., Forman, S. J., Gillessen-Kaesbach, G., Hoover-Fong, J., Koster, B., Pauli, R. M., Reardon, W., Zaidi, S. A., Zasloff, M., Morhart, R., Mundlos, S., Groppe, J., and Shore, E. M. (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1, Hum. Mutat. 30, 379-390.
12. Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T. J., Choi, I. H., Connor, J. M., Delai, P., Glaser, D. L., LeMerrer, M., Morhart, R., Rogers, J. G., Smith, R., Triffitt, J. T., Urtizberea, J. A., Zasloff, M., Brown, M. A., and Kaplan, F. S. (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva, Nat. Genet. 38, 525-527.
13. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action, J. Clin. Invest. 108, 1167-1174.
14. Russell, R. R., 3rd, Li, J., Coven, D. L., Pypaert, M., Zechner, C., Palmeri, M., Giordano, F. J., Mu, J., Birnbaum, M. J., and Young, L. H. (2004) AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury, J. Clin. Invest. 114, 495-503.
15. Sasaki, H., Asanuma, H., Fujita, M., Takahama, H., Wakeno, M., Ito, S., Ogai, A., Asakura, M., Kim, J., Minamino, T., Takashima, S., Sanada, S., Sugimachi, M., Komamura, K., Mochizuki, N., and Kitakaze, M. (2009) Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase, Circulation 119, 2568-2577.
16. Vazquez-Martin, A., Oliveras-Ferraros, C., Lopez-Bonet, E., and Menendez, J. A. (2009) AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor, Cell Cycle 8, 3679-3683.
17. Bussmann, J., Lawson, N., Zon, L., and Schulte-Merker, S. (2008) Zebrafish VEGF receptors: a guideline to nomenclature, PLoS Genet. 4, e1000064.
18. Isogai, S., Lawson, N. D., Torrealday, S., Horiguchi, M., and Weinstein, B. M. (2003) Angiogenic network formation in the developing vertebrate trunk, Development (Cambridge, U.K.) 130, 5281-5290.
19. Covassin, L. D., Villefranc, J. A., Kacergis, M. C., Weinstein, B. M., and Lawson, N. D. (2006) Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish, Proc. Natl. Acad. Sci. U.S.A. 103, 6554-6559.
20. Habeck, H., Odenthal, J., Walderich, B., Maischein, H., and Schulte- Merker, S. (2002) Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis, Curr. Biol. 12, 1405-1412.
21. Heinke, J., Wehofsits, L., Zhou, Q., Zoeller, C., Baar, K. M., Helbing, T., Laib, A., Augustin, H., Bode, C., Patterson, C., and Moser, M. (2008) BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis, Circ. Res. 103, 804-812.
22. Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R. L., Zhao, Q., Pukac, L., Lowik, C. W., and ten Dijke, P. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis, J. Cell Sci. 120, 964-972.
23. Fraley, M. E., Rubino, R. S., Hoffman, W. F., Hambaugh, S. R., Arrington, K. L., Hungate, R. W., Bilodeau, M. T., Tebben, A. J., Rutledge, R. Z., Kendall, R. L., McFall, R. C., Huckle, W. R., Coll, K. E., and Thomas, K. A. (2002) Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics, Bioorg. Med. Chem. Lett. 12, 3537-3541.
24. Lawson, N. D., and Weinstein, B. M. (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish, Dev. Biol. 248, 307-318.
25. Daniels, R. N., Kim, K., Lebois, E. P., Muchalski, H., Hughes, M., and Lindsley, C. W. (2008) Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines, Tetrahedron Lett. 49, 305-310.
26. Fraley, M. E., Hoffman, W. F., Rubino, R. S., Hungate, R. W., Tebben, A. J., Rutledge, R. Z., McFall, R. C., Huckle, W. R., Kendall, R. L., Coll, K. E., and Thomas, K. A. (2002) Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors, Bioorg. Med. Chem. Lett. 12, 2767-2770.
27. Cuny, G. D., Yu, P. B., Laha, J. K., Xing, X., Liu, J. F., Lai, C. S., Deng, D. Y., Sachidanandan, C., Bloch, K. D., and Peterson, R. T. (2008) Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors, Bioorg. Med. Chem. Lett. 18, 4388-4392.
28. Zilberberg, L., ten Dijke, P., Sakai, L. Y., and Rifkin, D. B. (2007) A rapid and sensitive bioassay to measure bone morphogenetic protein activity, BMC Cell Biol. 8, 41.
29. Fujii, M., Takeda, K., Imamura, T., Aoki, H., Sampath, T. K., Enomoto, S., Kawabata, M., Kato, M., Ichijo, H., and Miyazono, K. (1999) Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation, Mol. Biol. Cell 10, 3801-3813. (Pubitemid 29534026)
30. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, Cancer Res. 59, 99-106.
31. Daniels, R. N., Kim, K., Lebois, E. P., Muchalski, H., Hughes, M., and Lindsley, C. W. (2008) Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines, Tetrahedron Lett. 49, 305-310.
32. Fraley, M. E., Hoffman, W. F., Rubino, R. S., Hungate, R. W., Tebben, A. J., Rutledge, R. Z., McFall, R. C., Huckle, W. R., Kendall, R. L., Coll, K. E., and Thomas, K. A. (2002) Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors, Bioorg. Med. Chem. Lett. 12, 2767-2770.
33. Fraley, M. E., Rubino, R. S., Hoffman, W. F., Hambaugh, S. R., Arrington, K. L., Hungate, R. W., Bilodeau, M. T., Tebben, A. J., Rutledge, R. Z., Kendall, R. L., McFall, R. C., Huckle, W. R., Coll, K. E., and Thomas, K. A. (2002) Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics, Bioorg. Med. Chem. Lett. 12, 3537-3541.
34. Miyaura, N., and Suzuki, A. (1995) Palladium-catalyzed crosscoupling reactions of organoboron compounds, Chem. Rev. 95, 2457-2483.
35. King, A. O., Okakadao, N., and E.-i, N. (1977) Highly general stereo-, regio-, and chemo-selective synthesis of terminal and internal conjugated enynes by the Pd-catalyzed reaction of alkynylzinc reagents with alkenyl halides, J. Chem. Soc., Chem. Comm. 683-684.